(Q43605867)

25 November 2017

Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia (English)

1 reference

25 November 2017

1 reference

5

1 reference

25 November 2017

Nørgaard JM

1

1 reference

25 November 2017

Langkjer ST

series ordinal

2

1 reference

25 November 2017

Palshof T

series ordinal

3

1 reference

25 November 2017

Pedersen B

series ordinal

4

1 reference

25 November 2017

1 March 2001

1 reference

European Journal of Haematology

25 November 2017

1 reference

25 November 2017

66

1 reference

25 November 2017

160-167

1 reference

25 November 2017

3

1 reference

Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia.

25 November 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00361.X

Use of the MTT assay for rapid determination of chemosensitivity of human leukemic blast cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00361.X

Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00361.X

Primary Bioassay of Human Tumor Stem Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00361.X

In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00361.X

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00361.X

Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO)

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00361.X

MDR1 gene expression and drug resistance of AML cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00361.X

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00361.X

Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00361.X

RELATION OF BLAST CELL SURVIVAL AND PROLIFERATION TO CHEMOTHERAPY RESISTANCE IN AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00361.X

Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00361.X

7 January 2021

Leukaemia cell drug resistance and prognostic factors in AML.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00361.X

7 January 2021

Specific minor chromosome deletions consistently occurring in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00361.X

7 January 2021

An in vitro chemosensitivity test for the screening of anti-cancer drugs in childhood leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00361.X

7 January 2021

Short-term treatment for acute myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00361.X

7 January 2021

10.1034/J.1600-0609.2001.00361.X

Identifiers

DOI

1 reference

25 November 2017

1 reference